Table 2:
SUCRA analysis results of MASH treatment for ≥30% decline in MRI-PDFF
| Treatment | SUCRA |
|---|---|
| 12 weeks | |
| Pegozafermin | 95.23 |
| Aldafermin | 86.34 |
| Efruxifermin | 76.79 |
| Denifanstat | 60.85 |
| PXL770 | 54.13 |
| Resmetirom | 53.58 |
| Vonafexor | 47.34 |
| IONIS-DGAT2Rx | 42.07 |
| Licogliflozin | 41.71 |
| EDP-305 | 27.80 |
| Placebo | 8.15 |
| TERN-101 | 6.00 |
| 24 weeks | |
| Efinopegdutide | 67.02 |
| Semaglutide + Firsocostat | 62.43 |
| Pegbelfermin | 61.68 |
| Semaglutide + Cilofexor | 60.86 |
| Efruxifermin | 59.87 |
| Selonsertib +/− Simtuzumab | 55.31 |
| Semaglutide | 52.35 |
| Aldafermin | 52.07 |
| Semaglutide + Cilofexor + Firsocostat | 51.37 |
| Tropifexor + Cenicriviroc | 49.57 |
| Simtuzumab | 46.44 |
| Pemafibrate | 38.81 |
| Tropifexor | 38.09 |
| Placebo | 37.99 |
| Cenicriviroc | 35.84 |
| JKB-121 | 30.34 |
| 48 weeks | |
| Semaglutide | 83.18 |
| Tropifexor | 82.87 |
| Tropifexor + Cenicriviroc | 58.00 |
| Pegbelfermin | 52.68 |
| Cenicriviroc | 28.30 |
| Placebo | 26.28 |
| Pemafibrate | 18.70 |
Legend: MRI-PDFF- Magnetic Resonance Imaging Proton Density Fat Fraction; MASH – Metabolic Associated Steatohepatitis; SUCRA – Surface Under the Cumulative Ranking Curve